RPL22P17

Across TCGA pan-cancer cohorts, RPL22P17 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RPL22P17 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RPL22P17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL22P17 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LIHC show a favorable association.

CHOL, KICH, and KIRC are the cancer types where RPL22P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.235	0.649	.005	57	view →
KICH	OS	Tertile	All	0.876	1.000	.001	40	view →
KIRC	DFS	Tertile	IV	0.722	0.232	.027	18	view →
SKCM	OS	Tertile	IV	0.415	0.861	.014	18	view →
LIHC	OS	Tertile	All	0.879	0.718	.017	13	view →
THCA	OS	Tertile	All	0.981	0.991	.012	12	view →
GBM	DFS	Tertile	All	0.454	0.222	.017	9	view →
LUSC	OS	Quartile	All	0.750	0.649	.026	9	view →
READ	DFS	Tertile	IV	0.514	0.636	.008	9	view →
LAML	DFS	Quartile	All	0.670	0.413	.047	6	view →
ACC	DFS	Quartile	IV	0.641	0.263	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RPL22P17–CHOL (OS)

Open the CHOL breakdown →